ENGN Overview

enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).

Wall Street analysts forecast ENGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENGN is23.88 USD with a low forecast of 10.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

enGene Therapeutics Inc revenue for the last quarter amounts to -31.18M USD, increased 17.18

enGene Therapeutics Inc. EPS for the last quarter amounts to -29056000.00 USD, increased 11.78

enGene Therapeutics Inc (ENGN) has 45 emplpoyees as of May 10 2026.

Today ENGN has the market capitalization of 592.86M USD.